SCHEMBL8723604

SCHEMBL8723604

CCc1cccc(C(=O)Nc2ccc3scc(C4=CCN5CCCCC5CC4)c3c2)c1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.39
MAPT P10636 4/20 0.38
KMT2A Q03164 2/20 0.38
NPC1 O15118 2/20 0.38
MAPK1 P28482 2/20 0.38
BRAF P15056 1/20 0.37
MEN1 O00255 1/20 0.36
PARP1 P09874 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
TP53 P04637 3/20 0.35
L3MBTL3 Q96JM7 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
ACKR3 P25106 2/20 0.35
LMNA P02545 2/20 0.35
PDGFRB P09619 1/20 0.35
KDR P35968 1/20 0.35
RAB9A P51151 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8721851 0.93 TDP1 (0.38) TDP1MAPTNPC1MAPK1SMN1; SMN2
SCHEMBL8725926 0.91 TDP1 (0.41) TDP1MAPTKMT2ANPC1MAPK1
SCHEMBL8720823 0.90 TDP1 (0.39) TDP1MAPTKMT2ANPC1MAPK1
SCHEMBL8724153 0.89 POLB (0.41) TDP1MAPTKMT2ANPC1MAPK1
SCHEMBL8720711 0.89 TP53 (0.44) TDP1MAPTKMT2ANPC1MAPK1
SCHEMBL8720693 0.88 NPC1 (0.44) TDP1MAPTKMT2ANPC1MAPK1
SCHEMBL8723878 0.86 NR1H4 (0.46) TDP1MAPTKMT2ANPC1MEN1
SCHEMBL8721862 0.84 NPC1 (0.33) MAPTNPC1SMN1; SMN2LMNARAB9A
SCHEMBL8721285 0.84 KCNQ3 (0.40) MAPTKMT2ANPC1MEN1SMN1; SMN2
SCHEMBL8720781 0.84 MAPT (0.45) MAPTKMT2ANPC1MAPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ LP (CA) 2026-05-07 US disclosed
WO-2024073845-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ, LIMITED PARTNERSHIP (CA) 2024-04-11 WO disclosed
EP-0875513-A1 Substituted heteroaromatic 5-HT 1F agonists ELI LILLY AND COMPANY (US) 1998-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS HTR1F, HTR1A, HTR1D TDP1 1651/4885MAPT 3544/4885KMT2A 2708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.